Skip to main content

Advertisement

SpringerLink
Log in

Rheumatoid arthritis and cardiovascular disease

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting approximately 1% of the adult general population. Cardiovascular disease is recognized as the leading cause of death in RA patients, accounting for nearly 40% of their mortality. Patients with RA are at a twofold increased risk for myocardial infarction and stroke, with risk increasing to nearly threefold in patients who have had the disease for 10 years or more. Congestive heart failure appears to be a greater contributor to excess mortality than ischemia. This increased cardiovascular disease risk in RA patients seems to be independent of traditional cardiovascular risk factors. Pathogenic mechanisms include pro-oxidative dyslipidemia, insulin resistance, prothrombotic state, hyperhomocysteinemia, and immune mechanisms such as T-cell activation that subsequently lead to endothelial dysfunction, a decrease in endothelial progenitor cells, and arterial stiffness, which are the congeners of accelerated atherosclerosis observed in RA patients. This paper discusses pathogenic mechanisms, effects of methotrexate, tumor necrosis factor antagonists, steroids, and statins, with a perspective on therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gabriel SE: The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001, 27:269–281.

    Article  PubMed  CAS  Google Scholar 

  2. Van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002, 46:862–873.

    Article  PubMed  Google Scholar 

  3. Reilly PA, Cosh JA, Maddison PJ, et al.: Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990, 49:363–369.

    Article  PubMed  CAS  Google Scholar 

  4. Wolfe F, Mitchell DM, Sibley JT, et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481–494.

    Article  PubMed  CAS  Google Scholar 

  5. Solomon DH, Goodson NJ, Katz JN, et al.: Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006, 65:1608–1612.

    Article  PubMed  CAS  Google Scholar 

  6. Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303–1307.

    Article  PubMed  Google Scholar 

  7. Maradit-Kremers H, Crowson CS, Nicola PJ, et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52:402–411.

    Article  PubMed  Google Scholar 

  8. Nicola PJ, Crowson CS, Maradit-Kremers H, et al.: Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006, 54:60–67.

    Article  PubMed  Google Scholar 

  9. Nicola PJ, Maradit-Kremers H, Roger VL, et al.: The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52:412–420.

    Article  PubMed  Google Scholar 

  10. Di Franco M, Paradiso M, Mammarella A, et al.: Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 2000, 59:227–229.

    Article  PubMed  Google Scholar 

  11. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J: The increased risk of ventricular diastolic dysfunction and congestive heart failure in patients with rheumatoid arthritis is independent of the duration of the disease. Sem Arthritis Rheum 2005, 35:132–133.

    Article  Google Scholar 

  12. del Rincon ID, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737–2745.

    Article  PubMed  Google Scholar 

  13. Solomon DH, Curhan GC, Rimm EB, et al.: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50:3444–3449.

    Article  PubMed  Google Scholar 

  14. Escalante A, Haas RW, del Rincon I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005, 165:1624–1629.

    Article  PubMed  Google Scholar 

  15. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957–2963.

    Article  PubMed  Google Scholar 

  16. Hurt-Camejo E, Paredes S, Masana L, et al.: Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile [see comment]. Arthritis Rheum 2001, 44:2761–2767.

    Article  PubMed  CAS  Google Scholar 

  17. Park YB, Lee SK, Lee WK, et al.: Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701–1704.

    PubMed  CAS  Google Scholar 

  18. McMahon M, Grossman J, FitzGerald J, et al.: Proin-flammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006, 54:2541–2549.

    Article  PubMed  CAS  Google Scholar 

  19. Tabuchi M, Inoue K, Usui-Kataoka H, et al.: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007, 48:768–781.

    Article  PubMed  CAS  Google Scholar 

  20. Dursunolu D, Evrengul H, Polat B, et al.: Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005, 25:241–245.

    Article  CAS  Google Scholar 

  21. Asanuma Y, Kawai S, Aoshima H, et al.: Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis [see comment]. Arthritis Rheum 1999, 42:443–447.

    Article  PubMed  CAS  Google Scholar 

  22. Vis M, Nurmohamed MT, Wolbink G, et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005, 32:252–255.

    PubMed  CAS  Google Scholar 

  23. Dahlqvist SR, Engstrand S, Berglin E, Johnson O: Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006, 35:107–111.

    Article  PubMed  CAS  Google Scholar 

  24. Paolisso G, Valentini G, Giugliano D, et al.: Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metab Clin Exp 1991, 40:902–907.

    PubMed  CAS  Google Scholar 

  25. Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and highdensity lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002, 4:R5.

    Article  PubMed  Google Scholar 

  26. Hotamisligil GS, Arner P, Caro JF, et al.: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409–2415.

    Article  PubMed  CAS  Google Scholar 

  27. Liang CP, Han S, Senokuchi T, Tall AR: The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007, 100:1546–1555.

    Article  PubMed  CAS  Google Scholar 

  28. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:83–86.

    PubMed  CAS  Google Scholar 

  29. Bauer KA, ten Cate H, Barzegar S, et al.: Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989, 74:165–172.

    PubMed  CAS  Google Scholar 

  30. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR: Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994, 93:2073–2083.

    Article  PubMed  CAS  Google Scholar 

  31. Schecter AD, Spirn B, Rossikhina M, et al.: Release of active tissue factor by human arterial smooth muscle cells [see comment]. Circ Res 2000, 87:126–132.

    PubMed  CAS  Google Scholar 

  32. Clarke R, Daly L, Robinson K, et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease [see comment]. N Engl J Medicine 1991, 324:1149–1155.

    CAS  Google Scholar 

  33. Roubenoff R, Dellaripa P, Nadeau MR, et al.: Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997, 40:718–722.

    Article  PubMed  CAS  Google Scholar 

  34. Chiang E-PI, Bagley PJ, Selhub J, et al.: Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 2003, 114:283–287.

    Article  PubMed  CAS  Google Scholar 

  35. Chiang E-PI, Selhub J, Bagley PJ, et al.: Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1404–R1411.

    Article  PubMed  CAS  Google Scholar 

  36. Lazzerini PE, Capecchi PL, Bisogno S, et al.: Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 2003, 62:694–695.

    Article  PubMed  CAS  Google Scholar 

  37. van Ede AE, Laan RF, Blom HJ, et al.: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002, 41:658–665.

    Article  PubMed  Google Scholar 

  38. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  39. Pasceri V, Yeh ET: A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124–2126.

    PubMed  CAS  Google Scholar 

  40. Liuzzo G, Goronzy JJ, Yang H, et al.: Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000, 101:2883–2888.

    PubMed  CAS  Google Scholar 

  41. Gerli R, Schillaci G, Giordano A, et al.: CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744–2748.

    Article  PubMed  CAS  Google Scholar 

  42. Bryl E, Vallejo AN, Matteson EL, et al.: Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis [see comment]. Arthritis Rheum 2005, 52:2996–3003.

    Article  PubMed  CAS  Google Scholar 

  43. Kremer JM, Westhovens R, Leon M, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907–1915.

    Article  PubMed  CAS  Google Scholar 

  44. Hill JM, Zalos G, Halcox JPJ, et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593–600.

    Article  PubMed  Google Scholar 

  45. Grisar J, Aletaha D, Steiner CW, et al.: Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005, 111:204–211.

    Article  PubMed  Google Scholar 

  46. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al.: Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007, 56:809–819.

    Article  PubMed  CAS  Google Scholar 

  47. Ablin JN, Boguslavski V, Aloush V, et al.: Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 2006, 79:2364–2369.

    Article  PubMed  CAS  Google Scholar 

  48. Halcox JP, Schenke WH, Zalos G, et al.: Prognostic value of coronary vascular endothelial dysfunction [see comment]. Circulation 2002, 106:653–658.

    Article  PubMed  Google Scholar 

  49. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899–1906.

    PubMed  CAS  Google Scholar 

  50. Perticone F, Ceravolo R, Pujia A, et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191–196.

    PubMed  CAS  Google Scholar 

  51. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk? [comment]. Circulation 2002, 106:640–642.

    Article  PubMed  Google Scholar 

  52. Arosio E, De Marchi S, Rigoni A, et al.: Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis [see comment]. J Hypertens 2007, 25:1273–1278.

    Article  PubMed  CAS  Google Scholar 

  53. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al.: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637–1641.

    Article  PubMed  CAS  Google Scholar 

  54. Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184–2187.

    Article  PubMed  Google Scholar 

  55. Littler AJ, Buckley CD, Wordsworth P, et al.: A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997, 36:164–169.

    Article  PubMed  CAS  Google Scholar 

  56. Klimiuk PA, Sierakowski S, Latosiewicz R, et al.: Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002, 61:804–809.

    Article  PubMed  CAS  Google Scholar 

  57. Blacher J, Asmar R, Djane S, et al.: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999, 33:1111–1117.

    PubMed  CAS  Google Scholar 

  58. Boutouyrie P, Tropeano AI, Asmar R, et al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39:10–15.

    Article  PubMed  CAS  Google Scholar 

  59. Van Doornum S, McColl G, Jenkins A, et al.: Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function [see comment]. Arthritis Rheum 2003, 48:72–80.

    Article  PubMed  Google Scholar 

  60. Wong M, Toh L, Wilson A, et al.: Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003, 48:81–89.

    Article  PubMed  Google Scholar 

  61. Maki-Petaja KM, Hall FC, Booth AD, et al.: Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy [see comment]. Circulation 2006, 114:1185–1192.

    Article  PubMed  CAS  Google Scholar 

  62. Ebrahim S, Papacosta O, Whincup P, et al.: Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999, 30:841–850.

    PubMed  CAS  Google Scholar 

  63. Del Rincon I, Williams K, Stern MP, et al.: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48:1833–1840.

    Article  PubMed  Google Scholar 

  64. Roman MJ, Moeller E, Davis A, et al.: Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Inter Med 2006, 144:249–256.

    Google Scholar 

  65. McCarey DW, McInnes IB, Madhok R, et al.: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015–2021.

    Article  PubMed  CAS  Google Scholar 

  66. Maki-Petaja KM, Booth AD, Hall FC, et al.: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007, 50:852–858.

    Article  PubMed  CAS  Google Scholar 

  67. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006, 2:619–626.

    Article  PubMed  CAS  Google Scholar 

  68. Choi HK, Hernan MA, Seeger JD, et al.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173–1177.

    Article  PubMed  CAS  Google Scholar 

  69. Giles JT, Post W, Blumenthal RS, Bathon JM: Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2:320–329.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Emory University, 1364 Clifton Road NE, Suite 403C, Atlanta, GA, 30322, USA

    Arshed A. Quyyumi

Authors
  1. Saurabh S. Dhawan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arshed A. Quyyumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arshed A. Quyyumi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhawan, S.S., Quyyumi, A.A. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep 10, 128–133 (2008). https://doi.org/10.1007/s11883-008-0019-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0019-x

Keywords

Search

Navigation